

PubMed

Search: 20809335[uid]

U.S. National Library of Medicine
National Institutes of Health

Display Settings: Abstract

[Target Oncol.](#) 2010 Sep;5(3):201-10. Epub 2010 Aug 31.

Molecular markers in gliomas: impact for the clinician.

[Hofer S, Lassman AB.](#)

Department of Oncology, University Hospital Zürich, Zürich, Switzerland. Silvia.Hofer@usz.ch

Abstract

Over the last decade, understanding of glioma on a molecular level has greatly expanded. However, optimal incorporation of molecular markers into clinical care is controversial. We briefly review the potential utility of molecular stratification in refining histologic diagnosis, prognosis, and treatment decisions, focussing on 1p/19q co-deletion, MGMT promoter methylation, EGFR mutations, and IDH mutation. The most recently discovered IDH mutation is a striking example of a rapid implementation of a molecular marker for prognostication into common clinical use.

PMID: 20809335 [PubMed - indexed for MEDLINE]

Publication Types, MeSH Terms, Substances**LinkOut - more resources**